Merck's Pain Reliever Arcoxia Rejected by US Federal Advisory Panel
An advisory panel of the United States Food and Drug Administration (FDA) has rejected pharmaceutical giant Merck's bid to market Arcoxia,// a new osteoarthritis medication following concerns that it may carry cardiovascular risks.
Osteoarthritis is a joint disease that mostly affects cartilag...
Arcoxia Slammed –Nothing Better Than Vioxx Says FD
...ket due to safety reasons.
The arthritis drug arcoxia
which belongs to the same class of drugs as Vioxx...Yet, despite safety concerns in the United States, arcoxia
is still on sale in 63 other countries. Merck off...ing, and loss of motion of the joint.
is in the class of non-steroidal anti-inflammatory...